Overview
Provider Statement
This continuing medical education activity is provided by 
.
Support Statement
This activity is supported by an educational grant from Merck & Co., Inc.
Activity Description
Cytomegalovirus (CMV) is a common herpes virus that affects 50% to 80% of the US population. Disease from reactivation of CMV infection in a seropositive individual rarely occurs unless the immune system is suppressed due to either illness or drug therapies—a pivotal concern in patients receiving immunosuppressive therapy following hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT). Cytomegalovirus is the most important infectious agent following SOT and is a leading cause of illness in patients who have undergone allogeneic HSCT. In this educational activity, expert physicians examine the evidence behind CMV preemptive and prophylactic measures for transplant recipients as well as the use of conventional and emerging agents in prevention of CMV infection.
Target Audience
The intended audience for the activity is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus (CMV).
Learning Objective(s)
Upon successful completion of this educational activity, participants should be better able to:
- Apply the evidence regarding the use of prophylactic and preemptive measures to prevent CMV disease in transplant recipients.
- Assess the latest clinical evidence regarding antivirals and vaccines for use as prophylactic or preemptive anti-CMV therapy in transplant recipients.
- Evaluate the safety and resistance profiles of conventional and emerging therapies used to treat or prevent CMV infection.
Activity Chair
Francisco M. Marty, MD, FIDSA
Associate Professor of Medicine
Harvard Medical School
Associate Physician, Brigham and Women’s Hospital
Staff Physician, Dana-Farber Cancer Institute
Boston, MA
Faculty
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of ID/IC/EH
University of Texas MD Anderson Cancer Center
Houston, TX
Kathleen M. Mullane, DO, PharmD, FIDSA, FAST
Professor of Medicine, Section of Infectious Diseases
Director, Infectious Diseases Clinical Trials
Immunocompromised Host Service
University of Chicago
Chicago, IL
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, January 10, 2020, through January 9, 2021.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
MIPS Qualifying Activity:
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
Activity Chair and Faculty report the following relationship(s)
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Consulting Fee: Achaogen, ADMA Biologics, Ansun BioPharma, Chimerix, Entasis, Janssen, Kyorin, Merck, Oxford Immunotec, Pulmotect, ReViral, Shire, Wockhardt, Xenex
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun, Chimerix, Merck, Oxford Immunotec, Pulmotect, Shire, Viracor
Francisco M. Marty, MD, FIDSA
Consulting Fee: Amplyx, Janssen, Merck, Regeneron
Contracted Research: Chimerix, Merck, Shire
Kathleen M. Mullane, DO, PharmD, FIDSA, FAST
Consulting Fee: ADMA, Chimerix, GlaxoSmithKline, Merck
Speakers Bureau: Merck
Non-CME Services Fees: Merck, Shire
Contracted Research: Ansun, Astellas, Chimerix, Finch Therapeutics, Qiagen, Scynexis, Summit
Reviewer reports the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at [email protected]
